DE60216151D1 - Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion - Google Patents

Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion

Info

Publication number
DE60216151D1
DE60216151D1 DE60216151T DE60216151T DE60216151D1 DE 60216151 D1 DE60216151 D1 DE 60216151D1 DE 60216151 T DE60216151 T DE 60216151T DE 60216151 T DE60216151 T DE 60216151T DE 60216151 D1 DE60216151 D1 DE 60216151D1
Authority
DE
Germany
Prior art keywords
virus
hiv infection
fusion peptide
long acting
against hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60216151T
Other languages
English (en)
Other versions
DE60216151T2 (de
Inventor
John Erickson
P Bridon
Martin Robitaille
Grant A Krafft
Dong Xie
Elena Afonina
Jun Liang
Meyer Sandra De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ConjuChem Biotechnologies Inc
Original Assignee
ConjuChem Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ConjuChem Biotechnologies Inc filed Critical ConjuChem Biotechnologies Inc
Publication of DE60216151D1 publication Critical patent/DE60216151D1/de
Application granted granted Critical
Publication of DE60216151T2 publication Critical patent/DE60216151T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE60216151T 2001-05-31 2002-05-31 Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion Expired - Lifetime DE60216151T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29424101P 2001-05-31 2001-05-31
US294241P 2001-05-31

Publications (2)

Publication Number Publication Date
DE60216151D1 true DE60216151D1 (de) 2006-12-28
DE60216151T2 DE60216151T2 (de) 2007-09-27

Family

ID=23132509

Family Applications (3)

Application Number Title Priority Date Filing Date
DE60216151T Expired - Lifetime DE60216151T2 (de) 2001-05-31 2002-05-31 Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion
DE60204137T Expired - Lifetime DE60204137T2 (de) 2001-05-31 2002-05-31 Langwirkende fusionspeptid-inhibitoren für hiv-infektion
DE60229677T Expired - Fee Related DE60229677D1 (de) 2001-05-31 2002-05-31 Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE60204137T Expired - Lifetime DE60204137T2 (de) 2001-05-31 2002-05-31 Langwirkende fusionspeptid-inhibitoren für hiv-infektion
DE60229677T Expired - Fee Related DE60229677D1 (de) 2001-05-31 2002-05-31 Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion

Country Status (12)

Country Link
US (2) US7741453B2 (de)
EP (1) EP1390399B1 (de)
JP (2) JP4463545B2 (de)
AT (3) ATE345353T1 (de)
AU (1) AU2002302277A1 (de)
CA (1) CA2448891A1 (de)
DE (3) DE60216151T2 (de)
DK (1) DK1479691T3 (de)
ES (2) ES2242860T3 (de)
HK (1) HK1071379A1 (de)
PT (1) PT1479691E (de)
WO (1) WO2002096935A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
ES2334106T3 (es) 1999-05-17 2010-03-05 Conjuchem Biotechnologies Inc. Inhibidores peptidos de fusion de larga vida contra infecciones virales.
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
DE60006100T2 (de) * 1999-05-17 2004-07-01 Conjuchem, Inc., Montreal Lang wirkende insulinotrope peptide
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US7601691B2 (en) * 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
AU2002233089B2 (en) 2001-02-16 2005-12-22 Conjuchem Biotechnologies Inc. Long lasting glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal diseases and disorders
ATE345353T1 (de) 2001-05-31 2006-12-15 Conjuchem Biotechnologies Inc Langwirkende fusionspeptidinhibitoren gegen hiv- infektion
NZ567952A (en) * 2003-03-24 2009-12-24 Sequoia Pharmaceuticals Inc Long acting biologically active conjugates
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
EP2418281B1 (de) 2003-10-24 2016-06-01 Gencia Corporation Verfahren und Zusammensetzungen zur Abgabe von Polynukleotiden
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
DK1745078T3 (da) * 2004-04-23 2009-10-26 Conjuchem Biotechnologies Inc Fremgangsmåde til oprensning af albuminkonjugater
WO2005108418A1 (en) * 2004-05-06 2005-11-17 Conjuchem Biotechnologies Inc. Compounds for specific viral target
US8039432B2 (en) * 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
AU2006329215A1 (en) * 2005-12-22 2007-06-28 Conjuchem Biotechnologies Inc. Process for the production of preformed conjugates of albumin and a therapeutic agent
US20090099074A1 (en) * 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
US20090088378A1 (en) * 2007-01-12 2009-04-02 Omar Quraishi Long lasting inhibitors of viral infection
AU2008254767A1 (en) * 2007-05-16 2008-11-27 Conjuchem Biotechnologies Inc. Cysteic acid derivatives of anti-viral peptides
WO2008144590A2 (en) * 2007-05-16 2008-11-27 Conjuchem Biotechnologies Inc. Long lasting modified antifusogenic peptide for preventing hiv infection
GB0720503D0 (en) * 2007-10-22 2007-11-28 Angeletti P Ist Richerche Bio New compound
CA2708762A1 (en) * 2007-12-11 2009-06-18 Conjuchem Biotechnologies Inc. Formulation of insulinotropic peptide conjugates
US8815295B1 (en) 2011-12-22 2014-08-26 Alabama State University Anti respiratory syncytial virus peptide functionalized gold nanoparticles
AU2013263349B2 (en) 2012-05-17 2016-09-08 Extend Biosciences, Inc Carriers for improved drug delivery
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
JP6946182B2 (ja) 2014-10-22 2021-10-06 エクステンド バイオサイエンシズ インコーポレーテッドExtend Biosciences, Inc 治療用ビタミンdコンジュゲート
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652629A (en) 1985-07-03 1987-03-24 The Salk Institute For Biological Studies Synthetic peptide-based anti-rabies compositions and methods
US5612034A (en) 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
DE69326069T2 (de) 1992-07-20 2000-03-23 Univ Durham Zusammensetzungen die die hiv replikation inhibieren
GB9316895D0 (en) 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
EP0602290B1 (de) 1992-12-04 1999-08-25 ConjuChem, Inc. Antikörper-konjugiertes-Hepatitis B-Oberflächenantigen und dessen Verwendung
US5614487A (en) 1993-05-28 1997-03-25 Genentech, Inc. Sustained release pharmaceutical composition
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US6017536A (en) 1993-06-07 2000-01-25 Trimeris, Inc. Simian immunodeficiency virus peptides with antifusogenic and antiviral activities
US6342225B1 (en) 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
WO1996005389A1 (en) 1994-08-15 1996-02-22 B-Level Corp. Auxiliary surface-forming member for construction elements
US6103236A (en) 1995-05-10 2000-08-15 Kyowa Hakko Kogyo Co., Ltd. Toxin conjugates
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US6150088A (en) * 1997-04-17 2000-11-21 Whitehead Institute For Biomedical Research Core structure of gp41 from the HIV envelope glycoprotein
ATE406577T1 (de) 1997-11-07 2008-09-15 Conjuchem Biotechnologies Inc Methoden zum screening von affinitätsmarker- bibliotheken
CA2301799C (en) 1997-11-07 2007-08-07 Conjuchem, Inc. Novel conjugates of opioids and endogenous carriers
US6107489A (en) 1998-03-17 2000-08-22 Conjuchem, Inc. Extended lifetimes in vivo renin inhibitors
AU748496B2 (en) 1998-03-23 2002-06-06 Conjuchem, Inc. Local delivery of long lasting therapeutic agents
US6258782B1 (en) 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6656906B1 (en) 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
JP2002534059A (ja) 1998-10-13 2002-10-15 ザ ユニバーシティ オブ ジョージア リサーチファウンデーション,インコーポレイティド 安定化された生物活性ペプチドおよび同定、合成および使用方法
US20030190740A1 (en) 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
CA2359892A1 (en) 1999-01-08 2000-07-13 Panacos Pharmaceuticals, Inc. Methods of eliciting broadly neutralizing antibodies targeting hiv-1 gp41
ES2334106T3 (es) 1999-05-17 2010-03-05 Conjuchem Biotechnologies Inc. Inhibidores peptidos de fusion de larga vida contra infecciones virales.
JP4209086B2 (ja) 1999-05-17 2009-01-14 コンジュケム バイオテクノロジーズ インコーポレイテッド 長期持続性抗新脈管形成ペプチド
US20090175821A1 (en) 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
WO2000069900A2 (en) 1999-05-17 2000-11-23 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
DE60006100T2 (de) 1999-05-17 2004-07-01 Conjuchem, Inc., Montreal Lang wirkende insulinotrope peptide
DE19926154A1 (de) 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
DE19926475A1 (de) 1999-06-10 2000-12-14 Ktb Tumorforschungs Gmbh Träger-Pharmaka-Konjugate
JP2003508501A (ja) 1999-09-07 2003-03-04 コンジュケム,インコーポレーテッド 生物学的結合のための肺送達
US7090851B1 (en) 1999-09-10 2006-08-15 Conjuchem Inc. Long lasting fusion peptide inhibitors of viral infection
JP4925540B2 (ja) 1999-12-16 2012-04-25 ホワイトヘッド インスチチュート フォアー バイオメディカル リサーチ 5−ヘリックスタンパク質
ATE345353T1 (de) 2001-05-31 2006-12-15 Conjuchem Biotechnologies Inc Langwirkende fusionspeptidinhibitoren gegen hiv- infektion
US7575750B2 (en) 2002-09-24 2009-08-18 Frontiers Biotechnologies Col, Ltd. Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity
AP2005003294A0 (en) 2002-09-27 2005-06-30 Tanox Inc Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome
US7556813B2 (en) 2002-09-27 2009-07-07 Trimeris, Inc. Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides
WO2005007831A2 (en) 2003-07-18 2005-01-27 Vanderbilt University Compositions of protein mimetics and methods of using same against hiv-1, sars-cov and the like
DK1745078T3 (da) 2004-04-23 2009-10-26 Conjuchem Biotechnologies Inc Fremgangsmåde til oprensning af albuminkonjugater
WO2005108418A1 (en) 2004-05-06 2005-11-17 Conjuchem Biotechnologies Inc. Compounds for specific viral target
AU2006329215A1 (en) 2005-12-22 2007-06-28 Conjuchem Biotechnologies Inc. Process for the production of preformed conjugates of albumin and a therapeutic agent

Also Published As

Publication number Publication date
EP1390399B1 (de) 2005-05-11
DE60229677D1 (de) 2008-12-11
DE60204137T2 (de) 2006-01-26
JP4463545B2 (ja) 2010-05-19
DE60204137D1 (de) 2005-06-16
WO2002096935A3 (en) 2003-10-02
DK1479691T3 (da) 2007-03-12
ATE295370T1 (de) 2005-05-15
EP1390399A2 (de) 2004-02-25
ES2242860T3 (es) 2005-11-16
PT1479691E (pt) 2007-02-28
CA2448891A1 (en) 2002-12-05
ATE345353T1 (de) 2006-12-15
AU2002302277A1 (en) 2002-12-09
JP2005500274A (ja) 2005-01-06
US7741453B2 (en) 2010-06-22
DE60216151T2 (de) 2007-09-27
JP2008308506A (ja) 2008-12-25
ATE412667T1 (de) 2008-11-15
US20050065075A1 (en) 2005-03-24
ES2277173T3 (es) 2007-07-01
US20110166061A1 (en) 2011-07-07
WO2002096935A2 (en) 2002-12-05
HK1071379A1 (en) 2005-07-15

Similar Documents

Publication Publication Date Title
DE60216151D1 (de) Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion
NO20051969L (no) Nukleosidderivater for behandling av hepatitt C virusinfeksjon.
ATE387208T1 (de) Antivirale mittel aus pflanzenextrakten und deren verwendung zur behandlung viraler infektionen
WO2008144584A3 (en) Cysteic acid derivatives of anti-viral peptides
DE602006015861D1 (de) Antivirale verbindungen
ATE476983T1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen der atemwege
NO20070194L (no) Fremgangsmater for behandling av hepatitt C
ATE264914T1 (de) Antivirale proteine, dafür kodierende dna, und deren verwendung
WO2003051306A3 (en) N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections
BRPI0507675A (pt) derivados de 2'-c-metil nucleosìdeo
WO2007033444A3 (en) Antiviral therapy with carbohydrate binding agents
TW200733953A (en) Materials and methods for treating viral infections
NO20020571L (no) Peptider som blokkerer infeksjonsevnen, og fremgangsmåter for anvendelse av disse
WO2005007078A3 (en) Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (sars)
WO2008118849A3 (en) Hiv-1 protease inhibitors
CR7806A (es) Inhibidores de la fusion de derivados peptidos de la infeccion vih
DK1765370T3 (da) Parapox-vira i kombination med andre antivirale midler til behandling af HIV/AIDS
WO2007002172A3 (en) Hiv-1 protease inhibitors
ATE478679T1 (de) Verfahren zur anwendung von ionisierungsstrahlung bei einer hiv-infektionstherapie
EP1752469A3 (de) Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion
WO2008144590A3 (en) Long lasting modified antifusogenic peptide for preventing hiv infection
ATE481413T1 (de) Glutathionderivate und deren verwendung zur behandlung von viralen erkrankungen
CY1105997T1 (el) Mακρας διαρκειας αναστολεις πεπτιδιου συντηξης για μολυνση hiv
WO2004108128A1 (fr) Utilisation de bullatacine dans la fabrication de medicaments anti-sida
HRP20030701A2 (en) Natural antibodies active against hiv virus

Legal Events

Date Code Title Description
8364 No opposition during term of opposition